Biogen registers Phase 2 trial of felzartamab (BIIB148) in generalized myasthenia gravisNov 16Trial updateBiogenfelzartamab
Biogen posts Phase 4 RESPOND results for nusinersen after onasemnogene abeparvovecOct 30Trial updateBiogennusinersen
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Biogen registers Phase 2 felzartamab trial in IgA nephropathyOct 22Weekly roundup, 3 itemsBiogenfelzartamabUpdated
Samsung Bioepis gets label supplement approved for Byooviz ranibizumab biosimilarSep 1Regulatory decisionBiogenHarrow Inc
Biogen posts Q2 2026 results, sets five late-stage readouts over next four quartersJul 29Quarterly updateBiogenfelzartamab
Biogen Phase 2 felzartamab trial in Graves' disease recruiting since July 2026Jul 23Trial updateBiogenfelzartamab